Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:52 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $78.3M (132642.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 20, 2025 | Mar 29, 2024 | Mar 29, 2023 | Mar 2, 2022 |
| Revenue | $59.0K | $441.0K | $1.92M | $18.1M | $5.40M |
| Cost of revenue | – | – | $1.28M | $3.43M | $1.49M |
| Research and development | $50.1M | $24.4M | $13.8M | $31.3M | $59.8M |
| Selling, general and administrative | $22.9M | $17.2M | $10.3M | $20.7M | $21.8M |
| Operating income | -$72.9M | -$68.5M | -$27.4M | -$37.4M | -$82.1M |
| Income tax | $165.0K | $114.0K | $14.0K | $28.0K | -$196.0K |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M | -$84.4M |
| EPS, basic | $-5.84 | $-7.94 | $-114.00 | $-4.43 | – |
| EPS, diluted | $-5.84 | $-20.91 | $-114.00 | $-4.43 | – |
| Weighted shares, basic | 13.4M | 4.43M | 277.7K | 9.41M | – |
| Weighted shares, diluted | 13.4M | 7.50M | 277.7K | 9.41M | – |
| Margins and growth | |||||
| Operating margin | -123601.7% | -15535.6% | -1421.6% | -207.4% | -1521.6% |
| Net margin | -132642.4% | -7965.8% | -1639.5% | -230.8% | -1563.1% |
| Revenue growth, year over year | −86.6% | −77.1% | −89.3% | +234.4% | −19.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 20, 2025 | Mar 29, 2024 | Mar 29, 2023 | Mar 2, 2022 |
| Cash and equivalents | $15.9M | $134.5M | $7.42M | $13.2M | $54.6M |
| Short-term investments | $82.5M | – | – | – | – |
| Inventory | – | – | $0 | $20.0K | $38.0K |
| Total current assets | $105.3M | $138.9M | $8.39M | $16.4M | $61.8M |
| Goodwill | $10.5M | $10.5M | $10.5M | $14.4M | $14.4M |
| Intangible assets | – | – | – | $0 | $38.0K |
| Total assets | $116.5M | $150.7M | $21.0M | $33.4M | $80.2M |
| Accounts payable | $137.0K | $283.0K | $446.0K | $2.88M | $3.37M |
| Total current liabilities | $12.9M | $6.96M | $4.62M | $22.1M | $19.9M |
| Total liabilities | $33.4M | $17.7M | $13.7M | $44.3M | $57.1M |
| Shareholders' equity | $83.0M | $133.0M | $7.30M | -$10.9M | $23.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 20, 2025 | Mar 29, 2024 | Mar 29, 2023 | Mar 2, 2022 |
| Operating cash flow | -$51.5M | -$49.1M | -$30.7M | -$26.8M | -$70.9M |
| Capital expenditures | – | $0 | $158.0K | $95.0K | $113.0K |
| Free cash flow | – | -$49.1M | -$30.8M | -$26.8M | -$71.0M |
| Depreciation and amortization | $344.0K | $169.0K | $158.0K | $166.0K | $1.66M |
| Stock-based compensation | $13.6M | $5.85M | $3.48M | $7.55M | $8.17M |
| Investing cash flow | -$81.7M | $356.0K | -$133.0K | -$95.0K | -$113.0K |
| Financing cash flow | $14.6M | $175.8M | $25.0M | -$14.7M | $106.8M |
| Net change in cash | -$118.6M | $127.1M | -$5.77M | -$41.5M | $35.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 23086.4% | 1327.0% | 180.7% | 41.8% | 151.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 57.8M | +218.9% | SEC |
| Aug 3, 2026 | 53.6M | +307.8% | SEC |
| May 8, 2026 | 52.6M | +385.5% | SEC |
| Mar 18, 2026 | 22.8M | +113.5% | SEC |
| Nov 3, 2025 | 18.1M | +74.5% | SEC |
| Aug 6, 2025 | 13.2M | +1,171.8% | SEC |
| May 7, 2025 | 10.8M | +947.0% | SEC |
| Mar 17, 2025 | 10.7M | +932.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-12 in Q3 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.